Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Market Opportunities Biosimilar Liraglutide Access Markets, Emerging Geography Expansion, and Precision Obesity Medicine Unlock Underserved GLP-1 Market Growth Segments Biosimilar liraglutide entry represents the first generic competition wave for the GLP-1 weight loss drug category, expanding access for the 480 million obesity patients in lower-middle income countries for whom USD 1,000-plus monthly branded drug pricing is permanently inaccessible
Oxidative stress and lipotoxicity
Your provider may need to document previous weight loss attempts, BMI criteria, or related health conditions
During your consultation, we will evaluate your medical history, lifestyle, and weight loss goals to determine the best treatment plan for you
US$ 27.90
US$ 29.43
US$ 23.57
